Status and phase
Conditions
Treatments
About
In this clinical trial, the investigator will clarify the difference in pharmacokinetics between the group single dose Cavir Tab. 0.5mg and single dose Cavir Tab. 0.5mg with high fatty meal for healthy adult volunteer.
The investigators evaluate the effect of food intake on the absorption of Cavir Tab. 0.5mg.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Subject has a history of clinically significant disease.
Subject has a digestive disease (Crohn's disease, ulcer, acute or chronic pancreatitis etc) or abdomen surgery (exclude, simple appendectomy or hernia operation).
Subject has a hypersensitivity history which is clinically significance or additives.
Subject is inappropriate to screening (disease history, physical examination, vital sings, electrocardiogram, laboratory test etc.)
Subject has a laboratory test result as indicated by and one of the following.
Subject is hypertension(SBP>140mmHg or DBP>90mmHg) or hypotension(SBP<90mmHg, DBP<60mmHg)
Subject has a drug abusing history.
Subject is currently abusing alcohol (more than 210 g/week), caffeine(more than 5cups/day) or smoking(more than half pack).
Primary purpose
Allocation
Interventional model
Masking
30 participants in 3 patient groups
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal